New outcomes study for ticagrelor (BRILINTA™) to examine longer-term treatment for post- ACS patients
Friday, 1 October 2010
Important notice for users
You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information.
I have read this warning and will not be using any of the contained product information for clinical purposes